In the trial reported by Regan et al. [22] including 2,537 participants randomized to tamoxifen or the aromatase inhibitor letrozole, two outcomes were analysed: (i) breast cancer-free interval (defined from recruitment to the first breast cancer event [local, regional, or distant recurrence] or a new invasive contralateral breast cancer) and (ii) hot flushes. The gene discussed is CYP19A1; the disease is breast cancer.